Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Kairos Pharma (KAPA) EBIT Margin (2024 - 2025)

Historic EBIT Margin for Kairos Pharma (KAPA) over the last 2 years, with Q1 2025 value amounting to 1.27%.

  • Kairos Pharma's EBIT Margin fell 17950200.0% to 1.27% in Q1 2025 from the same period last year, while for Jun 2025 it was 4.58%, marking a year-over-year change of. This contributed to the annual value of 2.34% for FY2024, which is 40833000.0% down from last year.
  • According to the latest figures from Q1 2025, Kairos Pharma's EBIT Margin is 1.27%, which was down 17950200.0% from 71.32% recorded in Q3 2024.
  • In the past 5 years, Kairos Pharma's EBIT Margin registered a high of 1850.0% during Q2 2024, and its lowest value of 1.27% during Q1 2025.